A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion
- Registry ID
- EUCTR2009-015918-22
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Novartis Pharma AG
- Start date
- 2010-04-27
- Completion date
- 2014-10-30
- Last update
- 2026-08-16
Conditions
- Trasplante renal
- renal transplantation
- De Novo renal transplantation
Summary
To demonstrate superior renal allograft function in de novo renal transplant recipients after early conversion from CNI to everolimus, assessed by Glomerular Filtration Rate (eGFR) estimated by the Modification of Diet in Renal Disease formula 4 (MDRD4) at Month 12 versus the active control
Locations
- , , Lithuania
- , , Austria
- , , Germany
- , , Greece
- , , Latvia
- , , Estonia
- , , Spain
- , , Italy
- , , Belgium
- , , Portugal
View on source registry